To further elaborate this model for developing salvage therapies, the Center for AIDS Research has now begun a clinical trial based on the lab findings concerning various drug combinations' activity against resistant HIV isolates. Patients whose HIV has specific reverse transcriptase and protease gene mutations are enrolled in the trial and will receive a quadruple drug combination containing adefovir, efavirenz, ddI and hydroxyurea. The 24 volunteers will be monitored closely over a period of six months for drug toxicity and changes in viral RNA levels, CD4 cell counts and gene mutations. Reproduced with permission. Inc. All rights reserved.
Noncommercial reproduction is encouraged.
Subscription lists are kept confidential. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only.